Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies

Overview

Journal Antibodies (Basel)

Date 2024 Oct 25

PMID 39449328

Authors

Yuan Zong

Miki Miyagaki

Mingming Yang

Jing Zhang

Yaru Zou

Kyoko Ohno-Matsui

Koju Kamoi

Affiliations

Soon will be listed here.

Abstract

Background: Monoclonal antibodies (mAbs) have demonstrated substantial potential in the treatment of intraocular diseases. This review aimed to comprehensively evaluate the applications, efficacy, and safety of mAbs in the management of intraocular conditions.

Methods: A comprehensive literature search was conducted in major medical databases through July 2024. Relevant studies on monoclonal antibodies for intraocular diseases were included. Two independent researchers screened the literature, extracted data, and assessed study quality. Cost-effectiveness analyses were also reviewed.

Results: Anti-vascular endothelial growth factor (VEGF) antibodies, such as bevacizumab, ranibizumab, and aflibercept, showed significant therapeutic effects in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Tumor necrosis factor-alpha (TNF-α) inhibitors demonstrated promising results in treating noninfectious uveitis. Complement system-targeted therapies like pegcetacoplan offered new options for geographic atrophy. Anti-VEGF antibodies showed potential in managing retinopathy of prematurity (ROP). However, challenges persist, including high costs, potential drug resistance, and limited long-term safety data in certain scenarios.

Conclusions: Monoclonal antibodies are vital for treating intraocular diseases, but continuous innovation and rigorous clinical evaluation are essential. Future research should focus on developing novel delivery systems, exploring combination therapies, conducting long-term follow-up studies, and investigating personalized treatment strategies to provide safer, more effective, and cost-effective therapeutic solutions.

References

Zhang W, Liu Y, Sang A . Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. BMC Ophthalmol. 2022; 22(1):472. PMC: 9727869. DOI: 10.1186/s12886-022-02682-7. View

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

Sahni J, Patel S, Dugel P, Khanani A, Jhaveri C, Wykoff C . Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019; 126(8):1155-1170. DOI: 10.1016/j.ophtha.2019.03.023. View

Heier J, Lad E, Holz F, Rosenfeld P, Guymer R, Boyer D . Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023; 402(10411):1434-1448. DOI: 10.1016/S0140-6736(23)01520-9. View

Eser Ozturk H, Oray M, Tugal-Tutkun I . Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. Ocul Immunol Inflamm. 2017; 26(7):1005-1014. DOI: 10.1080/09273948.2017.1355471. View

Wallsh J, Gallemore R . Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options. Cells. 2021; 10(5). PMC: 8145407. DOI: 10.3390/cells10051049. View

Mugheddu C, Atzori L, Del Piano M, Lappi A, Pau M, Murgia S . Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017; 30(5). DOI: 10.1111/dth.12527. View

Baudin F, Benzenine E, Mariet A, Bron A, Daien V, Korobelnik J . Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France. JAMA Ophthalmol. 2018; 136(12):1352-1358. PMC: 6583044. DOI: 10.1001/jamaophthalmol.2018.3939. View

Zahavi D, Weiner L . Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020; 9(3). PMC: 7551545. DOI: 10.3390/antib9030034. View

10.

Krohne T, Liu Z, Holz F, Meyer C . Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012; 154(4):682-686.e2. DOI: 10.1016/j.ajo.2012.03.047. View

11.

Hernandez Garfella M, Palomares Fort P, Ivorra J, Cervera Taulet E . Aqueous Humor Levels of Different Interleukins 1-β, 2, 6 and 10, Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in Uveitis Treated with Adalimumab. J Ophthalmic Vis Res. 2015; 10(1):49-54. PMC: 4424719. DOI: 10.4103/2008-322X.156110. View

12.

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

13.

Sun Y, Wirta D, Murahashi W, Mathur V, Sankaranarayanan S, Taylor L . Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma. Ophthalmol Sci. 2023; 3(2):100290. PMC: 10130689. DOI: 10.1016/j.xops.2023.100290. View

14.

Do D, Pieramici D, van Lookeren Campagne M, Beres T, Friesenhahn M, Zhang Y . A phase ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy. Retina. 2013; 34(2):313-20. DOI: 10.1097/IAE.0b013e3182979ddd. View

15.

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

16.

Lu X, Sun X . Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther. 2015; 9:2311-20. PMC: 4410828. DOI: 10.2147/DDDT.S67536. View

17.

Epps S, Coplin N, Luthert P, Dick A, Coupland S, Nicholson L . Features of ectopic lymphoid-like structures in human uveitis. Exp Eye Res. 2019; 191:107901. PMC: 7029346. DOI: 10.1016/j.exer.2019.107901. View

18.

Norcia L, Kiappe O, Jorge E . Biological Therapy in Noninfectious Pediatric Uveitis: A Systematic Review. Clin Ophthalmol. 2021; 15:3765-3776. PMC: 8434856. DOI: 10.2147/OPTH.S322445. View

19.

Desideri L, Traverso C, Nicolo M, Munk M . Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Pharmaceutics. 2023; 15(5). PMC: 10222467. DOI: 10.3390/pharmaceutics15051413. View

20.

Ng C, Sy A, Cunningham Jr E . Rituximab for non-infectious Uveitis and Scleritis. J Ophthalmic Inflamm Infect. 2021; 11(1):23. PMC: 8364894. DOI: 10.1186/s12348-021-00252-4. View